Objective: To analyze the risk factors, presentation, etiologies, and outcomes of adult cancer patients with intracranial hemorrhage (IH).
Cerebrovascular disease is the second most common CNS complication in patients with cancer. 1 Intracranial hemorrhage (IH) accounts for nearly one-half of cerebrovascular events and is more likely to be symptomatic than ischemic lesions. 1 The causes of IH in the cancer population differ from the general population and vary based on the type of malignancy. Solid tumors typically cause IH from intratumoral hemorrhage (ITH), representing an average of 3.1% of spontaneous IH in large autopsy series, whereas hematologic malignancies may cause IH from coagulopathy or leukostasis. [1] [2] [3] IH generally occurs late in the course of malignancy, although it may be the first manifestation of cancer. [4] [5] [6] [7] [8] [9] [10] Most hemorrhages are intraparenchymal and can vary in presentation. 1, [11] [12] [13] IH in patients with cancer is often viewed as a catastrophic and terminal event, although limited data on outcome exist. 14, 15 Most existing literature is autopsy based or precedes the modern era of neuroimaging. Moreover, advances in oncologic therapies and neurointensive care have significantly changed the demographics, pathophysiology, and prognosis of these patients. The objective of this retrospective study was to analyze the clinical manifestations, causes, and treatments of IH in adult patients with cancer. METHODS We reviewed the records of all cancer patients with a radiologically confirmed diagnosis of intracerebral hemorrhage (ICH) or subarachnoid hemorrhage (SAH) who were evaluated by a neurologist between January 2000 and December 2007; patients were identified from the Department of Neurology database. Subdural and epidural hemorrhages were included only if they coexisted with an ICH or SAH.
We excluded patients who had postoperative hemorrhages. Patients with incomplete records and those aged 17 years or younger were also excluded. Patients with recurrent hemorrhages were included only once at the time of first hemorrhage. Most patients had excellent follow-up, and only 6 were not seen by a Memorial Sloan-Kettering Cancer Center (MSKCC) provider after October 2007. We had functional and vital status for all patients; disposition after ITH was known for all but 4. The number of patients with missing data for each clinical and laboratory variable is shown in table 1.
Clinical features, vascular risk factors, type and stage of cancer, prior and current cancer treatment, presentation, radiographic information, therapy, prognostic factors, and outcome were collected. Cancer diagnoses were confirmed pathologically in all but 2 patients, 1 with a meningioma and 1 with a brainstem glioma. The presence of active disease and systemic or CNS metastases were documented. Prior cranial irradiation or craniotomy and current chemotherapeutic agents were noted. Laboratory values at diagnosis were recorded, including complete blood count, glucose, creatinine, international normalized ratio (INR), partial thromboplastin time (PTT), D-dimer, and fibrinogen. The presence of antiplatelet or anticoagulant agents was documented. All patients had CT, MRI, or both. Hemorrhage location was categorized as supratentorial, infratentorial, lobar, basal ganglia, brainstem, or cerebellum. Hemorrhage size could not be determined because of the diffuse and multifocal nature of many bleeds. Presence and type of herniations and hydrocephalus were also noted. Etiology of hemorrhage was determined by the reviewer and could include multiple diagnoses. ITH consisted of any hemorrhage into an underlying tumor. Coagulopathy was diagnosed if any of the following parameters were fulfilled: platelets Ͻ100/mm 3 , INR Ͼ1.5, PTT Ͼ45 seconds, disseminated intravascular coagulation (DIC) (fibrinogen Ͻ200 mg/dL and D-dimer Ͼ290 ng/dL), or full-dose low-molecular-weight heparin within the past 48 hours. Leukostasis was defined as a white blood cell count greater than 100 ϫ 10 3 /mm 3 .
Treatment of hemorrhage was recorded. Treatment for increased intracranial pressure (ICP) consisted of osmotic diuresis or hyperventilation. The functional status of patients at discharge was determined retrospectively and categorized as completely independent, partially independent, completely dependent, death, and unknown. The disposition and survival of patients were also documented.
Survival was analyzed using the Kaplan-Meier method. Survival time was defined from the date of hemorrhage to the date of death or last follow-up. Survival between groups was compared using the log-rank test. Logistic regression models analyzed 30-and 90-day mortality, and predictors of mortality univariately. Factors univariately significant at the ␣ Յ0.05 level were included in a stepwise logistic regression model with entry and exit levels set at 0.10 to produce the final multivariate analyses. All analyses were performed in SAS 9.2 (SAS Institute Inc., Cary, NC).
Standard protocol approvals, registrations, and patient consents.
This study was approved by the MSKCC Institutional Review Board. Patients with primary brain tumors were the youngest cohort, with 47% aged 50 years or younger, whereas only 23% of patients with a solid tumor and 7% of those with hematopoietic tumors were in this age range. The median time from cancer diagnosis to hemorrhage was 28 months for solid tumors, 22 months for hematologic tumors, and 6 months for primary brain tumors. Almost half the patients (n ϭ 91, 44%) had a known primary or metastatic brain tumor at the time of hemorrhage. Fifty-four patients (26%) had received prior cranial radiation therapy, and 37 (18%) had received prior craniotomy. Half the patients (n ϭ 104) had received chemotherapy within the past 4 weeks. Five received antiangiogenic therapy with bevacizumab (n ϭ 4) or sunitinib (n ϭ 1); the patient receiving sunitinib had ITH with coagulopathy, but none of the patients receiving bevacizumab had ITH.
RESULTS
Presentation. The majority of patients were symptomatic (94%) from the hemorrhage (table 3) . Patients with primary brain tumors (18%) were more likely to be asymptomatic than patients with solid (4%) or hematopoietic tumors (3%). Hemiparesis (48%), headache (41%), and impaired consciousness (34%) were the most common symptoms or signs; few patients had seizures (17%) or coma (6%). Only 5% of patients were acutely hypertensive with a systolic blood pressure greater than 180 mm Hg or a diastolic blood pressure greater than 120 mm Hg at time of ICH. The mean white blood cell count was 7.8 ϫ 10 3 cells/mm 3 , and the mean creatinine was 1.1 mg/dL. Only 7% of patients had a serum glucose greater than 200 mg/dL. Nineteen patients had mild Radiographic diagnosis was established in all patients by CT (24%), MRI (12%), or both (64%). Most patients bled into the intracerebral compartment (87%), and nearly half (n ϭ 91, 44%) had multiple foci of hemorrhage. IH was usually supratentorial and equally dispersed between hemispheres of the brain (left 52%, right 48%). Infratentorial hemorrhages occurred in 37 patients (18%) and were most common in the cerebellum (n ϭ 29). Herniation was seen radiographically in 50 patients (24%), 38 subfalcine, 19 uncal, 14 transtentorial, and 6 tonsillar. Hydrocephalus of any form was seen in 37 patients (18%).
Etiology. ITH (61%) and coagulopathy (46%) were the most common causes of IH in our population (table 3) . Less common causes were head trauma (6%), hypertension (5%), hemorrhagic conversion of an ischemic stroke (4%), and venous thrombosis (2%). Only 1 patient with acute myelocytic leukemia had leukostasis-associated hemorrhage (white blood cells 150.1 ϫ 10 3 cells/mm 3 ), and this patient was also moderately thrombocytopenic. Etiology was multifactorial in 33% of patients and most commonly was due to the combination of ITH and coagulopathy (n ϭ 44, 21%). ITH occurred in isolation in 44% of patients with solid tumors and 47% of those with primary brain tumors. Conversely, patients with hematopoietic tumors were more apt to hemorrhage from coagulopathy in isolation (46%) or coagulopathy in conjunction with other, less frequent diagnoses (33%), such as trauma. SAH was multifactorial in 30% of cases and was most commonly due to coagulopathy (n ϭ 30), trauma (n ϭ 10), or ITH (n ϭ 6); aneurysmal SAH was rare (n ϭ 4).
Treatment. Steroids were administered to 156 patients (75%). Reversal of coagulopathy and prevention of hematoma expansion were attempted with platelet transfusion (29%), fresh-frozen plasma or cryoprecipitate infusion (21%), or vitamin K administration (19%). Craniotomy for ventriculostomy or resection was performed in 55 patients (26%), whereas emergency therapy for increased ICP was administered to 26 (13%). Forty-six percent of patients were treated with anticonvulsants, though many were already taking seizure medications before their hemorrhage. Forty-eight patients (23%) were ultimately treated with cranial irradiation.
Outcome. At the time of statistical analysis, only 11% of patients were alive. At discharge, 15% of patients were completely independent, 33% were partially independent, 30% were completely dependent, and 22% were dead. Patients with solid tumors had the best functional outcome at discharge, with 53% being completely or partially independent, compared with 44% of patients with primary brain tumors and 30% of patients with hematologic tumors. Patients with hematopoietic tumors had the highest rate of death during hospitalization (36%), whereas patients with primary brain tumors (8%) had the lowest. Thirty-day mortality was 31% and 1-year mortality was 78% for the entire cohort. Median survival for all patients was 3 months (95% confidence interval 2-4). A difference ( p ϭ 0.05) in survival existed among tumor subtypes, with median survival being 5.9 months for patients with primary brain tumors, 2.1 months for patients with solid tumors, and 1.5 months for patients with hematologic tumors (figure ). Median survival also varied based on etiology of hemorrhage and was 3.7 months for patients with ITH, 0.3 months for patients with coagulopathy, 1.8 months for patients with both ITH and coagulopathy, and 3.9 months for patients with other diagnoses ( p ϭ 0.009). The most common dispositions excluding death were home (50%), hospice (10%), acute rehabilitation (6%), subacute rehabilitation (5%), and transfer to another hospital (3%).
In the multivariate models, impaired consciousness, not having a primary brain tumor, multiple foci of hemorrhage, hydrocephalus, increased ICP treatment, and not receiving ventriculostomy were significant predictors of 30-day mortality (table 4). All of these variables, except not having a primary brain tumor, were also independently predictive of 90-day mortality. Additionally, hemiparesis and current chemotherapy were significant predictors of mortality at 90 but not 30 days via multivariate analysis. Neither anticoagulant nor antiplatelet use was a significant predictor of mortality. DISCUSSION Cancer is an important and common cause of IH. Clinical and autopsy studies have found that brain tumors represent 0.9% to 11% of spontaneous IH. 2, 7, 11, [16] [17] [18] [19] [20] [21] [22] The largest autopsy study of IH in patients with cancer was performed at MSKCC from 1970 to 1981 and identified 244 patients, 57% of whom were symptomatic. 1 Coagulopathy occurred in 57% of those with ICH, and 89% of these patients had hematologic malignancies, particularly leukemia (78%). ITH occurred in 38% of patients and was the second most common cause of ICH; all but 2 of these patients had a solid tumor, with melanoma and germ cell tumors being the most frequent. Hypertension was responsible for only 8% of parenchymal hemorrhages in this cohort.
Our report represents the largest clinical series of IH in patients with cancer. Systemic solid tumors were the most common underlying cancer, which differs from many previous studies where primary brain tumors accounted for the majority of malignancies. 13, 21, 23, 24 In one series of 110 patients with bleeding cerebral neoplasms, 77% had primary brain tumors and 23% had metastatic solid tumors. 21 Similarly, 62% of patients with ITH in a different cohort of 58 cases had primary brain tumors. 13 This changing demographic may represent longer survival of patients with solid tumors or the higher likelihood of primary brain tumors with IH to be clinically silent and thus not lead to acute neuroimaging. Abbreviations: ICP ϭ intracranial pressure; NS ϭ not significant. a Variables that did not reach statistical significance based on preset ␣ values are not listed.
Data are expressed as odds ratio (95% confidence interval, p value).
tially decreasing the number of larger and more disabling hemorrhages. This study describes the unique pathophysiology and outcome of patients with cancer and IH. ITH and coagulopathy cause most IHs in patients with cancer, whereas hypertension and other causes typical in the general community are rare. Changes in etiology of IH in patients with cancer parallel improvements in management of the underlying neoplasm, particularly in the hematologic malignancies. Prognosis is generally poor, although many patients retain independence after IH and ultimately succumb to their underlying malignancy and not the hemorrhage itself.
